Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant
- PMID: 36064752
- DOI: 10.1038/s41409-022-01790-8
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant
Abstract
We examined associations between specific antibiotic exposures and progression to lower respiratory tract disease (LRTD) following individual respiratory viral infections (RVIs) after hematopoietic cell transplantation (HCT). We analyzed allogeneic HCT recipients of all ages with their first RVI during the first 100 days post-HCT. For the 21 days before RVI onset, we recorded any receipt of specific groups of antibiotics, and the cumulative sum of the number of antibiotics received for each day (antibiotic-days). We used Cox proportional hazards models to assess the relationship between antibiotic exposure and progression to LRTD. Among 469 patients with RVI, 124 progressed to LRTD. Compared to no antibiotics, use of antibiotics with broad anaerobic activity in the prior 21 days was associated with progression to LRTD after adjusting for age, virus type, hypoalbuminemia, neutropenia, steroid use, and monocytopenia (HR 2.2, 95% CI 1.1-4.1). Greater use of those antibiotics (≥7 antibiotic days) was also associated with LRTD in adjusted models (HR 2.2, 95% CI 1.1-4.3). Results were similar after adjusting for lymphopenia instead of monocytopenia. Antibiotic use is associated with LRTD after RVI across different viruses in HCT recipients. Prospective studies using anaerobe-sparing antibiotics should be explored to assess impact on LRTD in patients undergoing HCT.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients.Biol Blood Marrow Transplant. 2018 Nov;24(11):2293-2301. doi: 10.1016/j.bbmt.2018.05.016. Epub 2018 May 16. Biol Blood Marrow Transplant. 2018. PMID: 29777867 Free PMC article.
-
Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2019 Jan;25(1):163-171. doi: 10.1016/j.bbmt.2018.08.021. Epub 2018 Aug 25. Biol Blood Marrow Transplant. 2019. PMID: 30149147 Free PMC article. Clinical Trial.
-
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation.J Infect Dis. 2024 Jan 12;229(1):83-94. doi: 10.1093/infdis/jiad268. J Infect Dis. 2024. PMID: 37440459
-
Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients.J Clin Virol. 2022 Jun;150-151:105152. doi: 10.1016/j.jcv.2022.105152. Epub 2022 Apr 4. J Clin Virol. 2022. PMID: 35447514 Free PMC article. Review.
-
Risk factors for severity in seasonal respiratory viral infections and how they guide management in hematopoietic cell transplant recipients.Curr Opin Infect Dis. 2023 Dec 1;36(6):529-536. doi: 10.1097/QCO.0000000000000968. Epub 2023 Sep 20. Curr Opin Infect Dis. 2023. PMID: 37729657 Review.
Cited by
-
The intestinal microbiota and cellular therapy: implications for impact and mechanisms.Blood. 2024 Oct 10;144(15):1557-1569. doi: 10.1182/blood.2024024219. Blood. 2024. PMID: 39141827 Review.
-
Susceptibility to and severity of SARS-CoV-2 infection according to prescription drug use-an observational study of 46,506 Danish healthcare workers.PLoS One. 2024 Nov 27;19(11):e0311260. doi: 10.1371/journal.pone.0311260. eCollection 2024. PLoS One. 2024. PMID: 39602471 Free PMC article.
References
-
- Pinana JL, Gomez MD, Perez A, Madrid S, Balaguer-Rosello A, Gimenez E, et al. Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. Transpl Infect Dis. 2018;20:e12926. - PubMed - PMC - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical